Integration of Palliative Care into Heart Failure Care: Consensus-Based Recommendations from HFSA Out Now!

Heart Failure Seminar: Focus on Novel and Emerging Myocarditides: Recognition and Management

August 13, 2024 - August 13, 2024 | Virtual

Faculty

Faculty Disclosures

The Heart Failure Society of America (HFSA) is committed to ensuring balance, independence, objectivity, and scientific rigor in its educational activities. HFSA has a disclosure policy that requires oral presenters to disclose all relevant financial relationships for themselves and their spouse or partner during the past 24-months with any commercial entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on patients and related to the content of the activity, whether or not these commercial entities are supporters of the activity. Speakers will have a disclosure slide at the beginning of each presentation. All potential conflicts of interests have been resolved in accordance with the ACCME Updated Standards for Commercial Support. 
 
The following faculty and/or accreditors with ability to control content for this activity have no conflict of interest: 

  • Craig Beavers, PharmD 
  • Janet Crawford, APRN, SNP, MBA, MSN, ACNP-BC, FNP 
  • Shauna Wheeler, MS (CE Reviewer) 

The following faculty and/or accreditors with ability to control content for this activity have listed the below disclosures: 

  • W.H. Tang, MD – Consultant: Alexion Pharmaceuticals, Alleviant Medical, Bristol-Myers Squibb, CardiaTec Biosciences, Cardiol Therapeutics, Genomics plc, Intellia, Salubris Biotherapeutics, Sequana Medical, WhiteSwell, Zehna Therapeutics LLC, Kiniksa Pharmaceuticals (Ended), Renovacor Inc (Ended); Steering Committee Member (No Financial Relationship): Applied Therapeutics; Research Support: Alnylam Pharmaceuticals, Bristol-Myers Squibb, Cardurion Pharmaceuticals, Cordion, AstraZeneca (Ended), BioCardia (Ended), Salubris Biotherapeutics (Ended), Pfizer (Ended) 
  • Freny Vaghaiwalla Mody, MD – Research: National Institutes of Health, Merck, LivaNova, Novartis 

 

Off-Label Disclosure 
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and  is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.